Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050141 · ClinicalTrials.gov registry record · Phase 2
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00050141 is a Phase 2 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 121 participants.
The verdict
NCT00050141, a Phase 2 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of tipifarnib to standard letrozole therapy leads to a better response to treatment for your cancer in comparison to letrozole plus a placebo. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI). It blocks proteins that make cancer cells grow.
Interventions
- DRUG ZARNESTRA, tipifarnib, R115777
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2002-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050141
The ClinicalTrials.gov registry entry for NCT00050141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZARNESTRA, tipifarnib, R115777 is the first listed.
NCT00050141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050141 about?
NCT00050141 is a clinical study titled "Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer". The purpose of this study is to determine if the addition of tipifarnib to standard letrozole therapy leads to a better response to treatment for your cancer in comparison to letrozole plus a placebo. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI). It blocks prot...
What is the current status of trial NCT00050141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2002-09. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00050141?
The interventions under investigation include: ZARNESTRA, tipifarnib, R115777 (DRUG).
Who is sponsoring clinical trial NCT00050141?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.